Over the past few decades, discovering new anticancer drugs was considered one of the biggest challenges for researchers. In this study, two series of acylhydrazones Z1-6 and hydrazones K1-6 were synthesized via reacting isoniazid or 2-hydrazinopyridine with some aromatic heterocyclic aldehydes under acidic conditions. The structures of all compounds were proven spectrophotometrically using proton nuclear magnetic resonance (1HNMR) and carbon-13 NMR (13CNMR), in addition to liquid chromatography-mass (LCMS) spectra, infrared (IR) spectra, and elemental analyses. Our compounds were evaluated for their anticancer activity against three types of cancer cells: colon HCT-116, lung A-549, and MCF-7 breast Adenocarcinoma cancer cells by the SRB method. Compounds Z3 and K4 showed the highest inhibition against colon cancer cells with IC50 values of 1.59 and <1 μM, respectively. Moreover, flowcytometric analysis revealed the ability of Z3 to cause cell cycle arrest at sub G1 phase and S phase in HCT-116 colon cancer cell line, in addition to prominent apoptotic effects. Subsequently, molecular docking was conducted to gain insight into the plausible mechanism of action for the most active compounds Z3 and K4 and it suggested Topoisomeras I as a potential biological target of the new counterparts. Absorption, Distribution, Metabolism Excretion, and Toxicity (ADMET) study predicted physicochemical and pharmacokinetic aspects. Furthermore, density functional theory (DFT) was carried out to better understand the structural properties, stability, and chemical reactivity of the most promising derivatives. In summary, this study offers new anticancer candidates with acylhyrazone/hydrazone scaffolds which may need further optimization.
扫码关注我们
求助内容:
应助结果提醒方式:

